Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 9/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20962658 | 0.95 | SCD5 (0.46) | CYP3A4CYP2D6CYP1A2CYP2C9USP2 | |
| SCHEMBL20382070 | 0.93 | CYP11B2 (0.43) | CYP3A4CYP2D6CYP1A2CYP2C9USP2 | |
| SCHEMBL20965473 | 0.93 | SCD5 (0.48) | CYP3A4CYP2D6CYP1A2CYP2C9USP2 | |
| SCHEMBL17946542 | 0.87 | SCD5 (0.45) | CYP2D6USP2SCD5RORC | |
| SCHEMBL31425405 | 0.87 | CYP3A4 (0.45) | CYP3A4CYP2D6CYP1A2CYP2C9USP2 | |
| SCHEMBL23551919 | 0.86 | RORC (0.48) | USP2SCD5RORC | |
| SCHEMBL15871707 | 0.86 | USP2 (0.45) | CYP2D6USP2ALDH1A1TSHRSCD5 | |
| SCHEMBL23763011 | 0.84 | CYP2D6 (0.50) | CYP3A4CYP2D6CYP1A2CYP2C9USP2 | |
| SCHEMBL25052826 | 0.82 | HPGD (0.46) | CYP3A4CYP2D6CYP1A2CYP2C9USP2 | |
| SCHEMBL14240265 | 0.82 | HPGD (0.46) | CYP3A4CYP2D6CYP1A2CYP2C9USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CYP3A4 2929/4885CYP2D6 3133/4885CYP1A2 3702/4885 |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP3A4 2929/4885CYP2D6 3133/4885CYP1A2 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.